Citations

Clear

77 citation(s) found for "Pelletier, C".

RALLY MF: A phase 2 Study of DISC-0974, an anti-hemojuvelin antibody, in patients with myelofibrosis and anemia
Gangat, Naseema , Tefferi, Ayalew , Michaelis, Laura C. , Islam, Prioty , Rampal, Raajit K. , Swords, Ronan , Pettit, Kristen , Bhatt, Sima , Buch, Akshay, Pelletier, Olivia, Savage, Will, Pettit, Kristen , Bose, Prithviraj , Hexner, Elizabeth O. , Gerds, Aaron T. , Jain, Akriti Gupta , Talpaz, Moshe , Halpern, Anna B.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 2042-2042

10.1182/blood-2025-2042 Get It

Abstract Background Hepcidin, a central regulator of iron homeostasis, is pathologically elevated in patients with myelofibrosis (MF) and anemia. Chronic hepcidin elevation limits iron availability for red blood cell production and contributes to the onset and severity of anemia, for which there is a large unmet need for safe and effective treatments. DISC-0974 is an investigational, first-in-class, monoclonal antibody that blocks hemojuvelin, a co-receptor in the bone morphogenetic protein-signaling pathway driving hepcidin expression. In studies involving healthy volunteers (Novikov, et al, J Clin Pharmacol 2024:64(8):953-962) and participants with MF (Gangat et al, Blood 2024;144(Suppl1):657), DISC-0974 dosing resulted in reduced serum hepcidin levels and increased serum iron, with a favorable safety profile. Clinically meaningful improvements in anemia were also observed: 50% of non–transfusion-dependent (nTD) participants achieved a mean hemoglobin increase of ≥1.5 g/dL for at least 12 weeks, while 80% of participants with low transfusion burden (TD low) and 40% of participants with high transfusion burden (TD high) achieved transfusion independence (TI) for ≥16 and ≥12 consecutive weeks, respectively. Aims This Phase 2, open-label, multiple-ascending dose study (NCT05320198) assesses efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) in participants with MF. Methods Participants were enrolled into 3 primary cohorts (n=30 per cohort), categorized by the units of red blood cells transfused in the 84 days prior to screening: nTD (hemoglobin <10 g/dL with 0 units), TD low (1-2 units), and TD high (3-12 units transfused). Additionally, an exploratory cohort of participants receiving concomitant treatment with momelotinib or pacritinib (n=10) was included. Eligible participants were ≥18 years of age with hemoglobin <10 g/dL or a transfusion requirement meeting World Health Organization diagnostic criteria for primary or secondary MF. A stable dose of concomitant hydroxyurea and/or Janus kinase (JAK) inhibitor (ruxolitinib and fedratinib for primary cohorts; momelotinib and pacritinib for exploratory cohort) was allowed. Major exclusion criteria included liver iron concentration ≥7 mg/g dry weight (TD high only) and nutritional, genetic, infectious, or autoimmune anemia. DISC-0974 was administered subcutaneously at a dose of 50 mg once monthly for a total of 6 doses. Dose escalation to 75 mg was required for inadequate or loss of response. Primary endpoints included evaluating hematologic response defined for TD low and TD high as TI during any 16- and 12-week consecutive period, respectively, and for nTD as a mean hemoglobin increase of ≥1.5 g/dL from baseline for at least 12 weeks. Secondary endpoints included PK/PD markers of iron regulation and safety assessments. Data were summarized using descriptive statistics. Results As of 01 July 2025, enrollment of the exploratory cohort of momelotinib was complete (n=10). Baseline hepcidin values in the exploratory cohort were similar (mean (SD) of 83.6 (62.8) ng/mL) to baseline hepcidin values from the DISC-0974 Phase 1b study (mean (SD) of 85.8 (71.0) ng/mL, n=35), and sustained hepcidin reduction was observed after DISC-0974 dosing. Early hematologic responses observed after 1 to 3 doses in the exploratory cohort were comparable to those reported in the Phase 1b study (Gangat et al, Blood 2024;144(Suppl1):657). Based on these initial data, the protocol was amended to allow concomitant momelotinib or pacritinib in all cohorts. Preliminary results, including baseline characteristics, PD, and hematologic responses across all cohorts, will be presented.
Transfusion of Amustaline/Glutathione Pathogen-reduced Red Blood Cells in Cardiac Surgery: A Randomized Phase 3 Clinical Trial
Sekela, Michael , Snyder, Edward L. , Toyoda, Yoshiya , Alsammak, Mohamed , Sodha, Neel R. , Beaver, Thomas M. , Pelletier, J. Peter R. , Gorham, James D. , McNeil, John W. , Pearl, Ronald G. , Nuttall, Gregory A. , Reece, T. Brett , Collaborators, and the ReCePI Study, Sekela, Michael E , Welsby, Ian J , Alsammak, Mohamed , Sodha, Neel R , Beaver, Thomas M , Pelletier, J Peter R , Gorham, James D , McNeil, John S , Sniecinski, Roman M , Nuttall, Gregory A , Sarode, Ravi , Benjamin, Richard J , Collaborators, and the ReCePI Study

Mayo Clinic

Anesthesiology | August 12, 2025 | Volume: 143 | Issue: 5 | Pages: 1196-1210

10.1097/aln.0000000000005716 | PMID 41085306 Get It

Background: Transfusion has a persistent low risk of transfusion-transmitted infection and transfusion-associated graft- versus -host disease that may be addressed using pathogen reduction. The Red Cell Pathogen Inactivation (ReCePI) trial tested whether amustaline/glutathione pathogen-reduced red cells are noninferior to conventional transfusions for support of acute surgical blood loss. Methods: A phase 3, double-blinded, noninferiority trial randomized cardiac or thoracic–aorta surgery patients with increased risk of red cell transfusion to receive pathogen-reduced or conventional red cells during and for 7 days postsurgery. The primary endpoint was the proportion of patients with acute kidney injury (AKI), which is defined as an increase from baseline of greater than or equal to 0.3 mg/dl serum creatinine within 48 h of surgery. Noninferiority was claimed if the upper bound 95% CI of the treatment difference was less than half (50%) of the observed conventional arm incidence. Adverse events and treatment-emergent red cell antibodies were assessed for 28 and 75 days, respectively. Results: A total of 581 subjects were randomized, and 321 (55%) were transfused with study red cells. Transfused subjects in both arms had similar baseline demographics, medical histories, hemoglobin levels, and surgical procedures. Hemoglobin day 3 nadir levels (8.6 g/dl [7.8 to 9.2] in the pathogen-reduced arm; 8.4 g/dl [7.8 to 9.3] in the conventional arm; P = 0.52) were comparable. Incidence of AKI by 48 h was 46 of 157 (29.3%) in the pathogen-reduced arm and 45 of 161 (28.0%) in the conventional arm (treatment difference, 0.7%; 95% CI, −8.9 to 10.4%; noninferiority margin, 14.0%; P = 0.001 for noninferiority). AKI within 7 days by Kidney Disease Improving Global Outcomes staging criteria was not different (59 of 159 [37.1%] in the pathogen-reduced arm; 55 of 162 [34.0%] in the conventional arm; P = 0.53), but stage III was more common in the pathogen-reduced arm (pathogen-reduced arm, 15 of 159 [9.4%]; conventional arm, 7 of 162 [4.3%]; P = 0.075). Of 159 pathogen-reduced red cell recipients, 5 (3.1%) developed specific, low-titer antibodies without evidence of hemolysis. Conclusions: The incidence of AKI in recipients of pathogen-reduced red cells was noninferior to conventional red cell transfusion. Treatment-emergent antibodies were uncommon and not clinically significant.
Characterizing the antibody response to amustaline/glutathione pathogen‐reduced red blood cells
Karim, Christopher, Panigrahi, Anil K. , Pearl, Ronald G. , Sodha, Neel R. , Beaver, Thomas M. , Pelletier, J. Peter R. , Nuttall, Gregory A. , Reece, T. Brett , Erickson, Anna , Hedrick, Teresa, Bentow, Stanley, Mufti, Nina, Varrone, Jeanne, Corash, Laurence M , Benjamin, Richard J , Hedrick, Teresa, Liu, Kathy

Mayo Clinic

Transfusion | December 25, 2024 | Volume: 65 | Issue: 2 | Pages: 344-353

10.1111/trf.18117 | PMID 39719927 Get It

AbstractBackgroundThe clinical significance of natural and treatment‐emergent antibodies specific for amustaline/glutathione pathogen‐reduced red blood cells (PRRBCs) is not known.Study Design and MethodsA Phase 3, randomized clinical trial of PRRBCs (ReCePI) compared PRRBCs with conventional RBCs in cardiac or thoracic‐aorta surgery. Subjects transfused during and for 7 days after surgery were screened for PRRBC‐specific antibodies at baseline, 28 and 75 days post‐surgery. Subjects with treatment‐emergent antibodies were assessed for evidence of hemolysis. Cryopreserved subject RBC samples were assayed by flow cytometry for circulating PRRBCs using an acridine‐specific (2S197‐2M1) monoclonal antibody, and for human IgG‐coated RBCs. RBC‐surface acridine density was quantitated using a commercial calibrated phycoerythrin (PE)‐bead panel.ResultsFive of 159 (3.1%) PRRBC and zero of 162 conventional RBC recipients developed treatment‐emergent PRRBC‐specific IgG, low titer antibodies detected 26–80 days post‐surgery after exposure to 1–3 PRRBC units, without clinical evidence of hemolysis. DAT and eluate were weak (w+) positive and PRRBC‐specific in one subject. A monocyte monolayer assay (MMA) was non‐reactive in the three subjects with an interpretable result. Flow cytometry demonstrated circulating PRRBCs in all five subjects expressing surface acridine concentrations at the limit of detection (approximately 150–301 PE molecules/RBC) compared with freshly transfused PRRBCs (approximately 7500 PE molecules/RBC). In some samples, loss of surface acridine expression could not be distinguished from clearance of the PRRBCs.DiscussionTreatment‐emergent PRRBC‐specific antibodies with the characteristics of nonclinically significant antibodies were detected in five subjects transfused with PRRBCs. Flow cytometry demonstrated persistent circulating PRRBCs with minimal surface acridine expression. (www.ClinicalTrials.gov Identifier NCT03459287).
A Phase 1b Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia
Gangat, Naseema , Foran, James M. , Rampal, Raajit K. , Michaelis, Laura C. , Islam, Prioty , Swords, Ronan , Bhatt, Sima , Buch, Akshay, Pelletier, Olivia, Savage, Will, Tefferi, Ayalew , Halpern, Anna B. , Bose, Prithviraj , Hexner, Elizabeth O. , Talpaz, Moshe

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 657-657

10.1182/blood-2024-203719 Get It

Background Hepcidin, a central regulator of iron homeostasis, is pathologically elevated in patients with myelofibrosis (MF) and anemia. Chronic hepcidin elevation limits iron availability for red blood cell production and contributes to onset and severity of anemia, for which there is a large unmet need for safe and effective treatments. DISC-0974 is an investigational, first-in-class, monoclonal antibody that blocks hemojuvelin, a co-receptor in the bone morphogenetic protein-signaling pathway driving hepcidin expression. A completed healthy volunteer study demonstrated serum hepcidin reductions, serum iron increases, and increasing trends in hematologic parameters, with no safety signal identified. Aims This Phase 1b/2, open-label, multiple-ascending dose study (NCT05320198) assessed safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and initial efficacy of DISC0974 in patients with MF and anemia. Methods Eligible participants were ≥18 years of age with intermediate-2 or high-risk MF and anemia. Anemia was defined as baseline hemoglobin (Hgb) <10 g/dL with or without intermittent transfusion requirement (non-transfusion dependent [nTD]) or transfusion dependent (TD), as defined by the IWG-MRT. A stable dose of concomitant hydroxyurea and/or Janus kinase (JAK) inhibitor was allowed. Major exclusion criteria included liver iron concentration ≥7 mg/g dry weight and nutritional, genetic, infectious, or autoimmune anemia. Dose escalation was based on a Bayesian optimal interval design with accelerated titration. DISC-0974 was administered subcutaneously monthly for 6 doses. Primary endpoints included evaluating DISC-0974 safety and tolerability. Secondary endpoints included PK/PD markers of iron regulation and hematologic parameters. Hematologic response was defined for TD as transfusion independence (TI) during any 12-week consecutive period and for nTD as ≥1.5 g/dL Hgb increase from baseline at any time point. Durability was evaluated as mean Hgb ≥1.5 g/dL above baseline during any 12-week period. Data were summarized using descriptive statistics. Results At the time of data cut, 34 participants were enrolled at 5 dose levels: 14 mg (n=1), 28 mg (n=7), 50 mg (n=12), 75 mg (n=8), and 100 mg (n=6). Treatment with DISC-0974 resulted in meaningful and sustained hepcidin reductions with mean change from baseline (mean 88.2 ng/mL; range [8.7, 374.7]) reaching over 80% across treated participants. This corresponded to iron mobilization at all dose levels. Efficacy Hematologic responses were evaluated in participants dosed at 28 to 100 mg. Responses were achieved independent of baseline transferrin saturation (TSAT) values. Initial hematologic responses in nTD participants were observed around the time of administration of the second dose, with a rise in absolute reticulocyte count preceding responses. Mean erythropoietin values decreased from baseline (mean 68.2 mIU/mL; range [13.2, 1815]) in participants treated at 50 to 100 mg. Hemoglobin responses were achieved in 69% (20/29) of nTD participants; 60% of nTD participants (9/15) achieved a durable response. TSAT values above normal range (50%) were observed in all participants with a durable response. One of two evaluable TD participants achieved TI at the end of study. All evaluable participants with a baseline transfusion requirement (n=8) had ≥50% reduction in transfusions over a rolling 8-week window compared to baseline. Hematologic response was observed in 6 of 10 participants with concomitant JAK inhibitor therapy. Safety One adverse event (AE), diarrhea, was at least possibly related to DISC-0974 and reported in ≥2 participants. Grade 3 AEs included headache reported in 1 participant treated at 28 mg (not related to DISC-0974) and Grade 3 anemia reported in 2 participants treated at 28 mg and 4 participants treated at 50 mg (1 at 50 mg was deemed related to DISC-0974; all others were deemed not related). One serious AE of Grade 2 arthralgia was reported and deemed not related to DISC-0974. Summary/Conclusions DISC-0974 demonstrated acceptable safety and tolerability at all evaluated dose levels. Hematologic responses were achieved in nTD and TD participants, regardless of concomitant JAK inhibitor use. Sustained hepcidin reduction with DISC-0974 led to increased serum iron that preceded hematological response. Additional Phase 1b data, including longer follow-up, will be presented.
Transfusion Efficacy and Safety of Amustaline/Glutathione Pathogen-Reduced Red Blood Cells: Results of a Randomized, Controlled Phase III Trial
Snyder, Edward L. , Sekela, Michael , Toyoda, Yoshiya , Alsammak, Mohamed , Sodha, Neel R. , Beaver, Thomas M., Pelletier, J. Peter R. , Gorham, James D. , McNeil, John S. , Pearl, Ronald G. , Nuttall, Gregory A. , Reece, T. Brett , Davenport, Robertson D., Benharash, Peyman , Lopez‐Plaza, Ileana, Sadler, Patrick, Reik, Rita A., Mufti, Nina, Varrone, Jeanne, Benjamin, Richard J , Welsby, Ian J , Beaver, Thomas M. , Sniecinski, Roman M , Sarode, Ravi , Kaplan, Alesia , Ipe, Tina S. , Gammon, Richard R. , Corash, Laurence M , Liu, Kathy

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 5592-5592

10.1182/blood-2024-202164 Get It

Introduction: Red blood cell (RBC) transfusion is a lifesaving intervention with a low but persistent risk of transfusion-transmitted infection. Amustaline/glutathione RBC pathogen-reduction (PR) technology is designed to proactively inactivate a broad spectrum of viruses, bacteria, protozoa and leukocytes by chemically crosslinking nucleic acids and preventing replication and transcription. The Red Cell Pathogen Inactivation (ReCePI) trial was a Phase III, double-blinded, randomized non-inferiority study comparing PR and conventional RBCs for the support of acute anemia. Methods/Study Design: Complex cardiac or thoracic-aorta surgery patients received conventional (Control) or PR RBCs (Test) during and for 7 days after surgery. The protocol was conducted with ethics committee approval at all participating centers and written informed consent from all participants. Hemoglobin levels, blood utilization and serum creatinine were assessed as indicators of efficacy and oxygenation of tissues (Karkouti et al. Br J Anaesth. 2012; 109 Suppl 1: i29-i38). The primary endpoint was the incidence of acute kidney injury (AKI) measured as change in serum creatinine from baseline within 48 hours of surgery, a predictor of adverse postoperative outcomes including mortality by Day 30 post-surgery (Lassnig et al. Am Soc Nephrol 2004; 1597-1605). Secondary endpoints included AKI occurring up to 7 days post-surgery (KDIGO Clinical Practice Guideline for AKI, Kidney Inter, Suppl. 2012;2:1-138); death or the need for renal replacement therapy by 30 days post-surgery; PR RBC-specific antibodies; and death by day 75 post-surgery. With >292 subjects enrolled, the study had 80% power to demonstrate non-inferiority, assuming an AKI incidence of 30% with conventional RBCs and a non-inferiority margin of half the conventional RBC rate. Under these circumstances, an absolute treatment increase of 5% in the AKI rate in the PR RBC arm would fail the non-inferiority test. This work was supported by a contract with the US Biomedical Advanced Research and Development Authority (HHS010020160009c) with Cerus Corporation. Results: Five-hundred and eighty-one subjects were randomized and 321 (55%) transfused in 18 US hospitals. In the modified intent-to-treat analysis subjects receiving Test and Control RBCs had similar median [IQR] total blood loss (1500 [940-2475] mL Test, 1733 [1060-2880] mL Control, p=0.310) and comparable median hemoglobin levels at baseline and immediately post-surgery (9.8 [8.9-10.9] g/dL Test, 9.6 [8.6-10.6] g/dL Control, p=0.157) and for 7 days after surgery, The PR RBC arm was transfused with fewer RBCs, measured as total RBC Hb transfused over 7-days (169.0 [102.0-240.0] g Hb PR arm, 188.0 [126.0-295.0] g Hb, conventional RBC arm, p=0.008). The incidence of AKI was 29.3% (46/157) for Test and 28.0% (45/161) for Control. The treatment difference was 0.74% (95% CI -8.9, 10.4%, non-inferiority margin 14.0%, p=0.001 for non-inferiority). Non-inferiority was also achieved by the per protocol analysis. Average mean change in serum creatinine within 48 hours of surgery was comparable (Test 0.020, Control 0.23 mg/dL, P=0.515). Adverse events, serious adverse events and deaths on study were not different. Five of 159 (3.1%) PR RBC recipients developed low titer PR RBC-specific antibodies without clinical signs of hemolysis. Flow cytometry analysis revealed persistent circulating PR RBCs with uniform antigen loss (modulation). Low level human IgG antibody binding was demonstrated in 3 of 5 subjects. Conclusions: PR RBCs showed equivalent hemoglobin support for acute bleeding patients undergoing cardiac or thoracic-aorta surgery while using less transfused total RBC Hb over 7 days. The incidence of AKI in patients transfused with PR RBCs was non-inferior to that observed with conventional RBCs, indicative of effective tissue oxygenation. Treatment-related antibodies to PR-RBC were observed only in Test subjects, the antibodies were low titer, transient, without clinical hemolysis, and persistent circulating PR RBCs were detected with modulated low level acridine antigen expression (www.clinicaltrials.gov #NCT03459287).
Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study
Garcia‐Manero, Guillermo , Greenberg, Peter L. , Kennedy, Kyra Velázquez, Stahl, Maximilian , Mangaonkar, Abhishek A. , Garnier, Alice , Pelizzari, Anna Maria, Sockel, Katja , Lu, Hongbo, Manganelli, Luca, Ji, Lexiang , Zheng, Yan , Li, Yutong , Roy, Mike, Gatlik, Ewa , Singh, Arti, Beaulieu, Valérie , Gill, Harinder , Abaza, Yasmin , Haque, Tamanna Zohra , Porta, Matteo Giovanni Della , Ooi, Melissa , Xie, Zhuoer , Desai, Pinkal , Dezern, Amy Elizabeth , Meunier, Mathieu , Platzbecker, Uwe , Kishtagari, Ashwin , Li, Yutong, Roy, Mike, Pelletier, Marc R. , Rauch, Philipp J.

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 353-353

10.1182/blood-2024-198326 Get It

Introduction Patients with lower-risk (LR) myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) experience shortened survival and significant unmet medical need due to limited disease-modifying treatments. The NLRP3 pathway is activated in hematopoietic stem and progenitor cells and in the marrow microenvironment in myeloid neoplasms, contributing to ineffective hematopoiesis and clonal progression. DFV890, a small molecule NLRP3 inhibitor, blocks IL-1β and IL-18 secretion and pyroptotic cell death. Thus, DFV890 may disrupt the smoldering inflammation and provide disease-modifying benefits to patients by restoring normal hematopoiesis and suppressing clonal myeloproliferation. Methods This open-label, phase 1b, multicenter study evaluates DFV890 in patients with very low, low, or intermediate risk MDS per revised International Prognostic Scoring System (IPSS-R) criteria and low or intermediate-1 risk CMML per CMML-specific Prognostic Scoring System (CPSS) criteria (NCT05552469). The study comprises 2 parts: dose optimization and dose expansion. Eligible patients ≥18 years, with ECOG performance status ≤2, carrying a diagnosis of (a) IPSS-R-defined LR-MDS or (b) CPSS-defined LR-CMML, and have failed to respond to or not tolerated established first-line therapies as defined in the protocol. Key exclusion criteria include previous treatment with agents targeting the NLRP3 inflammasome and IL-1 pathway. DFV890 is administered orally twice daily (BID) for a minimum of 24 weeks (6 cycles of treatment) until treatment discontinuation. In the dose-optimization part, patients are randomized to receive either low- or high-dose, stratified by indication. Primary objectives are to assess safety and tolerability and determine the optimal for DFV890. Secondary objectives include assessment of pharmacokinetics, and evaluation of preliminary efficacy of DFV890 based on hematologic improvement (Garcia-Manero, Blood 2023). Exploratory objectives include assessment of peripheral cytokines and genetic alterations in blood and bone marrow, and patient-reported symptoms. Results As of April 15, 2024, 39 patients (median age, 74 years) with a median of 2 prior lines of therapy (range: 1-5) were treated with DFV890 in the dose-optimization part. Based on an 8-week screening period, 8 patients (20.5%) were RBC transfusion independent at baseline. Eighteen patients received low dose (17 with LR-MDS; 1 with LR-CMML), and 21 patients received high dose (18 with LR-MDS; 3 with LR-CMML). At data cutoff, 10 (25.6%) patients had discontinued treatment. Median duration of exposure was 10.7 weeks (range, 0.6-42.0 weeks). Adverse events (AEs) leading to study drug discontinuation were only reported in the high dose arm (2 patients, grade ≥3 neutropenia, n=1 and blood bilirubin increased, n=1). Treatment-related AEs (TRAEs) were reported in 10 patients (25.6%), with 4 (10.3%) experiencing grade ≥3 TRAEs (anemia [n=2], neutropenia, and rash [n=1 each]). No serious AEs related to DFV890 were reported. Peripheral cytokines were assessed as a marker of preliminary activity. Decrease in plasma IL-18 and IL-1RA levels observed in most patients, with a higher frequency in the low dose arm (IL-18 decreased in 8/8 patients in low dose arm vs. 4/7 in high dose arm; IL-1RA in 7/8 vs. 5/7), potentially due to less frequent dose interruptions. Changes in serum IL-6 levels were more heterogeneous; notably, among the patients with complete mutation and biomarker data, both patients with mutations in TET2 showed dramatic decreases in serum IL-6; IL-18 and IL-1RA also decreased in those patients. In addition, out of 8 patients who were transfusion-independent at baseline, 6 reported an increase in hemoglobin with treatment, 4 of whom with an increment >10% from baseline. Updated data including hematologic response assessment according to IWG will be presented at the meeting. Conclusions Preliminary findings from this ongoing study show a favorable safety profile in patients with LR-MDS and LR-CMML, in line with prior human studies with DFV890. Analysis of peripheral cytokines and hematologic parameters showed early indications of activity in a subset of patients, particularly those with mutations in TET2 and those transfusion independent at baseline. These findings will require confirmation with longer follow-up and in the dose expansion phase of the study.
The diagnostic value of the central vein sign in radiologically isolated syndrome
Landes-Château, Cassandre , Levraut, Michaël , Okuda, Darin T. , Themelin, Albert, Cohen, Mikaël , Kantarci, Orhun H. , Sıva, Aksel , Pelletier, Daniel, Mondot, Lydiane , Lebrun‐Frénay, Christine , Lebrun‐Frénay, Christine , Siva, Aksel , Okuda, Darin T , Cohen, Mikaël , Mondot, Lydiane

Mayo Clinic

Annals of Clinical and Translational Neurology | January 8, 2024 | Volume: 11 | Issue: 3 | Pages: 662-672

10.1002/acn3.51986 | PMID 38186317 Get It

AbstractObjectiveThe radiologically isolated syndrome (RIS) represents the earliest detectable preclinical phase of multiple sclerosis (MS). Increasing evidence suggests that the central vein sign (CVS) enhances lesion specificity, allowing for greater MS diagnostic accuracy. This study evaluated the diagnostic performance of the CVS in RIS.MethodsPatients were prospectively recruited in a single tertiary center for MS care. Participants with RIS were included and compared to a control group of sex and age‐matched subjects. All participants underwent 3 Tesla magnetic resonance imaging, including postcontrast susceptibility‐based sequences, and the presence of CVS was analyzed. Sensitivity and specificity were assessed for different CVS lesion criteria, defined by proportions of lesions positive for CVS (CVS+) or by the absolute number of CVS+ lesions.Results180 participants (45 RIS, 45 MS, 90 non‐MS) were included, representing 5285 white matter lesions. Among them, 4608 were eligible for the CVS assessment (970 in RIS, 1378 in MS, and 2260 in non‐MS). According to independent ROC comparisons, the proportion of CVS+ lesions performed similarly in diagnosing RIS from non‐MS than MS from non‐MS (p = 0.837). When a 6‐lesion CVS+ threshold was applied, RIS lesions could be diagnosed with an accuracy of 87%. MS could be diagnosed with a sensitivity of 98% and a specificity of 83%. Adding OCBs or Kappa index to CVS biomarker increased the specificity to 100% for RIS diagnosis.InterpretationThis study shows evidence that CVS is an effective imaging biomarker in differentiating RIS from non‐MS, with similar performances to those in MS.
Comorbid neurotrauma increases neurodegenerative-relevant cognitive, motor, and autonomic dysfunction in patients with rapid eye movement sleep behavior disorder: a substudy of the North American Prodromal Synucleinopathy Consortium
Ligman, Brittany R. , Bryant‐Ekstrand, Mohini , Keil, Allison , Powers, Katherine , Olivo, Cosette, Neilson, Lee E. , Pelletier, Amélie , Gagnon, Jean‐François , Liu, Lang , Forsberg, Leah K. , Fields, Julie A. , Ross, Owen A. , Howell, Michael J. , McLeland, Jennifer , Criswell, Susan R. , Miglis, Mitchell G. , Lee‐Iannotti, Joyce , Ju, Yo‐El S. , Lim, Miranda M. , Locke, Jessica, Amudson-Huffmaster, Sommer, Brushaber, Nellie, Chung, Jae Woo , Kam, Joshua De , Fischbach, Ellen, Ekelmans, Adrian , Keane, Marissa, Kraft, Ruth, MacKinnon, Colum D. , Miner-Rose, Daeva, Murphy, Samantha , Rivera, Adreanne, Sanchez, Sarahmay, Summers, Rebekah L. S. , Tiegan, Luke, Taylor, Leah, Timm, Paul, Tucker, Kelsey, Yu, Erik, Tran, Peter , Galasko, Douglas, Mignot, Emmanuel , Elliott, Jonathan E , Powers, Katherine , Neilson, Lee E , Gan-Or, Ziv , St Louis, E K , Ross, Owen A , Huddleston, Daniel E , Bliwise, Donald L , Avidan, Alon Y , Criswell, Susan R , During, Emmanuel , Miglis, Mitchell G , Boeve, Brad , Lim, Miranda M , Howell, Michael J , Elliott, Jonathan E. , Postuma, Ronald B. , Gan‐Or, Ziv , Yu, Eric , Louis, Erik K. St. , Huddleston, Daniel E. , Bliwise, Donald L. , Avidan, Alon Y. , Schenck, Carlos H. , Videnovic, Aleksandar , Shprecher, David , Boeve, Bradley F. , Duff, Kevin , Choudhury, Parichita , Stauder, Matthew J. , Taylor, Leah

Mayo Clinic

SLEEP | January 4, 2024 | Volume: 47 | Issue: 6 | Pages: No page available

10.1093/sleep/zsae007 | PMID 38181205 Get It

Abstract Study Objectives Rapid eye movement sleep behavior disorder (RBD) is strongly associated with phenoconversion to an overt synucleinopathy, e.g. Parkinson’s disease (PD), Lewy body dementia, and related disorders. Comorbid traumatic brain injury (TBI) and posttraumatic stress disorder (PTSD)—henceforth “neurotrauma” (NT)—increase the odds of RBD by ~2.5-fold and are associated with an increased rate of service-connected PD in Veterans. Thus, RBD and NT are both independently associated with PD; however, it is unclear how NT influences neurological function in patients with RBD. Methods Participants ≥18 years with overnight polysomnogram-confirmed RBD were enrolled between 8/2018 to 4/2021 through the North American Prodromal Synucleinopathy Consortium. Standardized assessments for RBD, TBI, and PTSD history, as well as cognitive, motor, sensory, and autonomic function, were completed. This cross-sectional analysis compared cases (n = 24; RBD + NT) to controls (n = 96; RBD), matched for age (~60 years), sex (15% female), and years of education (~15 years). Results RBD + NT reported earlier RBD symptom onset (37.5 ± 11.9 vs. 52.2 ± 15.1 years of age) and a more severe RBD phenotype. Similarly, RBD + NT reported more severe anxiety and depression, greater frequency of hypertension, and significantly worse cognitive, motor, and autonomic function compared to RBD. No differences in olfaction or color vision were observed. Conclusions This cross-sectional, matched case:control study shows individuals with RBD + NT have significantly worse neurological measures related to common features of an overt synucleinopathy. Confirmatory longitudinal studies are ongoing; however, these results suggest RBD + NT may be associated with more advanced neurological symptoms related to an evolving neurodegenerative process.